Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:601 (12 March), doi:10.1136/bmj.330.7491.601-a
| The first 150 words of the full text of this article appear below. |
EDITORThe Australian randomised trial of aortic aneurysm screening observed 18 deaths related to aneurysm in the group of men invited for screening and 25 in the control group.1 The corresponding reduction in mortality was 39% (relative risk 0.61, 95% confidence interval 0.33 to 1.11), which the authors summarise as showing that screening did not reduce overall death rates. The authors have fallen into the common trap of interpreting a non-significant difference as evidence of no difference.
The stated conclusion is all the more surprising given the available evidence from other randomised trials (table). In each trial, the number of aneurysm related deaths in the men invited for screening is lower than in the control group, and so the relative risks are all below 1. The widths of the confidence intervals vary according to the size and power of the trial. The largest trial, the multicentre aneurysm
Simon Thompson, director
simon.thompson@mrc-bsu.cam.ac.uk, MRC Biostatistics Unit, Cambridge CB2 2SR
Lois Kim, statistician
MRC Biostatistics Unit, Cambridge CB2 2SR
Alan Scott, research director
Scott Research Unit, St Richard's Hospital, Chichester PO19 4SE